Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-14
1998-06-02
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514844, 514852, 514874, 514880, A61K 3158
Patent
active
057600465
ABSTRACT:
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.
REFERENCES:
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4396615 (1983-08-01), Petrow et al.
patent: 4684635 (1987-08-01), Orentreich et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 4885289 (1989-12-01), Breuer et al.
patent: 5053403 (1991-10-01), Orentreich et al.
patent: 5175155 (1992-12-01), Juniewicz et al.
patent: 5228431 (1993-07-01), Giaretto
patent: 5571817 (1996-11-01), Rasmusson et al.
Abstracts of: Rhodes et al. J. Clin. Endocrinol. Metab 79(4):991-996 The Effects of Finasteride (Proscar) on Hair Growth. in Female Stumptail Macaques, 1994.
Simpson J. Dormatol. Treat. 1/2: 107-109 The Monogent of Andiogeneic Alopecia in Women, 1989.
U.S. application No. 08/596,339, Gormley et al., filed Oct. 1994.
Rittmaster et al., J. of Clin. Endoc. & Metab., vol. 65 (1987), pp. 188-193, "The Effects of N,N-diethyl-4-methyl-3-oxo-4-aza-5alpha-androstane-17beta-carboxamide . . . " Female Stumptail Balding Monkey.
Transcript, WNBC-TV, News 4 NY Live at Five, Nov. 29, 1993, Pisca trans Linlos in Women as Well As Men.
Sawaya et al., Dermatologic Therapy, vol. 11, No. 1 (1993), "The Antiandrogens", pp. 65-72 Androgive Oligecis in Women.
Shupack et al., Int. J. Dermat. 32(10) 1993, pp. 701-706, "Status of medical treatment for androgenic alopecia" I need footnote 656667 Yiang (1984) Rasmussen (1983) Oiani (1992) Any Females.
Gormley et al., J. Clin. Endo. Metab., vol. 70, pp. 1136-1141 (1990), "Effects of Finasteride (MK-906), a 5alpha-Reductase Inhibitor, on Circulating Androgens in Male Volunteers".
Transcript, WNBC-TV, News 4 NY Live at Five, Nov. 29, 1993.
Diani et al., J. Clin. Endoc. Metab., vol. 74, pp. 345-350 (1992), "Hair Growth Effects of Oral Admin. of Finasteride, a Steroid 5alpha-Reductase Inhibitor . . . ".
U.S. application No. 08/094,815 Rasmusson et al., filed Jul. 1993.
Imperato-McGinley et al., J. Clin. Endoc. Metab., vol. 70, pp. 777-782 (1990),"The 5-alpha reductase inhibitor finasteride comparison of male pseudohermaphrodites . . . ".
Bingham et al., J.. Endoc., vol. 57, pp. 111-121 (1973), "The metabolism of testosterone by human male scalp skin".
Stoner et al., Prostate, vol. 22, pp. 291-299 (1993),"Finasteride (MK-906) in the treatment of benign prostatic hyperplasia".
Stoner et al., J. Urol., vol. 147, pp. 1298-1302 (1992),"The clinical effects of a 5-alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia".
Sudduth et al., Pharmacotherapy, vol. 13, pp. 309-325 (Jul.-Aug. 1993), "Finasteride: The first 5-alpha-reductase inhibitor".
Gormley et al., New England J. Med., vol. 327, pp. 1185-1191 (1992), "The effect of finasteride in men with benign prostatic hyperplasia".
Matzkin et al., Clin. Endocrinol., vol. 37, pp. 432-436 (1992), "Prolonged treatment with finasteride (a 5-alpha-reductase inhibitor) dose not affect bone density and metabolism".
McConnell et al., J. Urol., vol. 143, No. 4, Suppl., p. 267A (1990), "The effects of low-dose finsteride (MK-906) on prostatic androgen levels in men with benign prostatic . . . ".
McConnell et al., J. Clin. Endoc. Metab., vol. 74, pp. 505-508 (Mar. 1992),"Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men . . . ".
Vermeulen et al., Eur. Urol., vol. 20, Supp. 1, pp. 82-86 (1991), "Hormonal effects of 5alpha reductase inhibitor (Finasteride) . . . ".
Vermeulen et al., Prostate, vol. 14, pp. 45-53 (1989), "Hormonal effects of an orally active 4-azasteroid inhibitor of 5-alpha-reductase in humans".
Metacalf et al., Trends Pharmacol. Sci., vol. 10,pp. 491-495 (1989), "Inhibitors of steroid 5-alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne".
Tempany et al., Prostate, vol. 22, pp. 39-42 (1993), "The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate . . . ".
Diani et al., Chem. Abstracts. vol. 116, Abstract No. 241714e.
Gormley et al., Prob. in Urology, vol. 5, No. 3, pp. 436-440 (1991), "The role of 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia".
Rittmaster et al., J. Clin. Endoc. Metab., vol. 65, No. 1, pp. 188-193 (1987), "The effects of N,N-diethyl-4-methyl-3-oxo-4-aza-5alpha-androstane-17beta-carboxamide, a 5alpha-reductase inhibitor and antiandrogen, on the development of baldness . . . ".
Mellin et al., J. Steroid Biochem. Mol. Biol., vol. 44, No. 2, pp. 121-131 (1993), "Azasteroids as inhibitors of testosterone 5alpha-reductase in mammalian skin".
Stoner, J. Steroid Biochem. Mol. Biol., vol. 37, No. 3, pp. 375-378 (1990), "The clinical development of 5alpha-reductase inhibitor, finasteride".
Dallob, J. Clin. Endoc. Metab., vol. 79, No. 3, pp. 703-706 (1994), "The effect of finasteride, a 5alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations . . . ".
Waldstreicher et al., J. Invest. Derma. 102(4) 1994, p 615, Item No. 549, "Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness".
Shupack et al., Int. J. Dermat. 31(10) 1993, pp. 701-706, "Status of medical treatment for androgenetic alopecia".
Kaufman et al., J. Invest. Derma. 102(4) 1994, p. 615, Item No. 550, "Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness".
Rhodes et al., J. Clin. Endocrin. & Metab. 79(4), 1994, pp. 991-996, "The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides)".
Steiner, Clin. Pharm. (USA) 12(1) 1993, pp. 15-23, "Finasteride: A 5alpha-reductase inhibitor".
Gormley, Drug Research Reports: The Blue Sheet, vol. 35, No. 20, 1992, pp. 6-7 "Proscar in clincals for chemoprevention following prosatectomy".
Sawaya et al, Dermatol. Clin. (USA) 11(1) 1993, pp. 65-72, "The antiandrogens: when and how they should be used".
Gormley Glenn J.
Kaufman Keith D.
Stoner Elizabeth
Waldstreicher Joanne
Fitch Catherine D.
Merck & Co. , Inc.
Nicholson William H.
Rose Shep K.
Winokur Melvin
LandOfFree
Method of treating androgenic alopecia with 5-.alpha.reductase i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating androgenic alopecia with 5-.alpha.reductase i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating androgenic alopecia with 5-.alpha.reductase i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1460117